Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75 years old from multiple Japanese institutes.

Kazuyuki NumakuraMizuki KobayashiShingo HatakeyamaSei NaitoYohei HorikawaToshikazu TanakaSachiko KamadaYumina MutoRyohei YamamotoAtsushi KoizumiTaketoshi NaraSohei KandaMitsuru SaitoShintaro NaritaTakamitsu InoueNaotake ShimodaNorihiko TsuchiyaChikara OhyamaTomonori Habuchi

Published in: International journal of clinical oncology (2020)

Nivolumab's effectiveness was comparable between the two patient groups, except for early AE-related discontinuation in the ≥ 75 year group.

Keyphrases

renal cell carcinoma
end stage renal disease
newly diagnosed
randomized controlled trial
prognostic factors
peritoneal dialysis
case report
patient reported
drug induced